As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors.
Gordon Mills, MD, PhD
Advertisement
Articles by Gordon Mills, MD, PhD
Advertisement
Latest Updated Articles
Homologous Recombination Deficiency and PARP Inhibition in Ovarian CancerPublished: June 6th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
5
